Compare Adaptive Biotechnologies Corp (ADPT) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PulteGroup, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while PulteGroup, Inc. trades at $124.17 (market cap $24.75B). The key difference: PulteGroup, Inc. is far larger — about 7.4× Adaptive Biotechnologies Corp's market cap, and PulteGroup, Inc. pays a 0.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PHM | |
|---|---|---|
Market Cap | $3.33B | $24.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $142.56 |
52-Week Low | $10.24 | $108.00 |
Enterprise Value | $3.19B | $24.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PulteGroup (PHM) trades at $129.92, down 2.81% on the day, amid mixed earnings performance with recent quarterly misses. The stock shows a bullish technical signal with strong moving averages and oversold RSI levels, while fundamentals reflect solid profitability with a 12.14% net margin and attractive valuation at a P/E of 12.71. Recent corporate developments include land acquisition for a new community, signaling growth initiatives.
The outlook is cautiously optimistic, supported by analyst consensus and a $144.17 price target, but risks include margin pressure from incentives and housing market sensitivity to interest rates. Investment appeal hinges on execution of margin recovery and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
